- Home
- TNXP vs KOD Comparison
TNXP vs KOD Comparison
Compare TNXP & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- KOD
- Stock Information
- Founded
- TNXP 2007
- KOD 2009
- Country
- TNXP United States
- KOD United States
- Employees
- TNXP N/A
- KOD N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNXP Health Care
- KOD Health Care
- Exchange
- TNXP Nasdaq
- KOD Nasdaq
- Market Cap
- TNXP 118.2M
- KOD 115.0M
- IPO Year
- TNXP N/A
- KOD 2018
- Fundamental
- Price
- TNXP $18.83
- KOD $3.77
- Analyst Decision
- TNXP Strong Buy
- KOD Hold
- Analyst Count
- TNXP 2
- KOD 3
- Target Price
- TNXP $585.00
- KOD $9.00
- AVG Volume (30 Days)
- TNXP 573.9K
- KOD 463.2K
- Earning Date
- TNXP 05-20-2025
- KOD 05-19-2025
- Dividend Yield
- TNXP N/A
- KOD N/A
- EPS Growth
- TNXP N/A
- KOD N/A
- EPS
- TNXP N/A
- KOD N/A
- Revenue
- TNXP $10,094,000.00
- KOD N/A
- Revenue This Year
- TNXP $12.17
- KOD N/A
- Revenue Next Year
- TNXP $789.15
- KOD N/A
- P/E Ratio
- TNXP N/A
- KOD N/A
- Revenue Growth
- TNXP 29.94
- KOD N/A
- 52 Week Low
- TNXP $6.76
- KOD $1.92
- 52 Week High
- TNXP $672.00
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- TNXP 53.35
- KOD 50.83
- Support Level
- TNXP $18.55
- KOD $3.66
- Resistance Level
- TNXP $21.99
- KOD $4.20
- Average True Range (ATR)
- TNXP 1.53
- KOD 0.49
- MACD
- TNXP 0.22
- KOD 0.00
- Stochastic Oscillator
- TNXP 58.64
- KOD 25.14
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.